Diseases information. Disorders. Treatment.

Porphyrias information
5-Aminolevulinic acid (ALA) dehydratase defect porphyria is a very rare type of porphyria that is caused by severe deficiency of 5-aminolevulinic acid dehydratase, the second enzyme of the heme biosynthetic pathway. It is inherited in autosomal recessive fashion, and fewer than 10 cases have been reported. The disease manifests itself in childhood and is usually associated with severe neurologic abnormalities suggestive of acute porphyric attacks. No effective therapy is known. Heme therapy or liver transplantation has had little effect on clinical course.
Porphyrias that are inherited in autosomal dominant fashion and thus are manifested in the heterozygous state may rarely occur in homozygous forms. Homozygous cases of variegate porphyria and hereditary coproporphyria have been described. Onset is in childhood, with presenting manifestations of severe photosensitivity and nonspecific neurologic symptoms. No specific treatments have been reported. Cialis professional discount pharmacy shop.
Hepatoerythropoietic porphyria is a homozygous form of porphyria cutanea tarda. The disease manifests itself in early childhood with severe skin problems that may lead to scarring and mutilation as in congenital erythropoietic porphyria. No effective treatment has been reported. According to one report, phlebotomy had no effect on porphyrin excretion or skin lesions.

Canadian viagra
Erythropoietic protoporphyria is manifested as acute photoreactivity of the skin in childhood. Typical symptoms are stinging pain or itching with subsequent swelling and erythema of the exposed skin within minutes to hours after sun exposure. Hepatobiliary complications may be associated with protoporphyria: early-onset cholelithiasis is found in 10% and signs of parenchymal liver disease are seen in 5 to 20% of patients.
The main biochemical finding is massively increased concentrations of free erythrocyte protoporphyrin: the values in symptomatic patients are usually more than 10 mumol per liter (the normal value is less than 1.0 mumol). Other biochemical findings are increased fecal protoporphyrin content in most patients and a characteristic plasma fluorescence spectrum.
Treatment
There is no specific treatment for erythropoietic protoporphyria. In most patients, beta carotene * increases tolerance to sunlight, but it has no influence on the erythrocyte or plasma porphyrin concentrations. The dosage of beta carotene must be adjusted to the level that clearly reduces photosensitivity. The daily effective dose varies, being 30 to 120 mg for children and 120 to 300 mg for adults. Cheap pharmacy viagra professional online. For therapeutic effects, the serum beta carotene concentration should be at least 600 to 800 mug per dL. The clinical effect is achieved concomitantly with carotenodermia, which develops over 3 to 6 weeks. In addition to beta carotene, topical sunscreens with high protection factor against long-wave ultraviolet radiation may be useful.
At present there is no effective treatment for prevention of liver complications. Many drugs such as cholestyramine, chenodeoxycholic acid, and heme have been used but without significant clinical effect. A liver transplantation is at present the only therapy for terminal liver failure associated with erythropoietic protoporphyria, although it poses specific problems. During surgery, phototoxic damage of abdominal wall and intestine, caused by standard lamps used in the operating room, has been reported. Thus, careful protection of the skin and modification of operating room lighting are needed. A long-term problem may be that protoporphyrin-induced damage may develop in the transplanted liver as well.

Congenital erythropoietic protoporphyria
Cheap propecia 5 mg
Congenital erythropoietic protoporphyria (Gunther’s disease) is a rare autosomal recessive disease that is manifested as severe photosensitivity. This leads to bullae, scarring, and, ultimately, mutilation of the hands, nose, ears, and so on. Hemolysis is often present, but its mechanism is poorly understood. Congenital erythropoietic porphyria is an incapacitating disease with considerable mortality. The patients excrete massive amounts of porphyrins (mainly uroporphyrin I). Many organs, including the teeth, accumulate porphyrins, which can be detected by red fluorescence under ultraviolet light.
There is no effective therapy. Protection of the skin from sunlight is important to prevent skin reactions, skin infections, and mutilation. Topical sunscreens that give protection against radiation in the 400-nm region may be used, but their value has not been proved. Transfusion of packed red cells effectively suppresses the overproduction of porphyrins, but weekly transfusions are impracticable and lead to iron accumulation. Charcoal (60 grams three times daily) has been reported to lead to clinical improvement and to long-term reduction in the levels of porphyrins. It is not known whether charcoal is effective in every patient. Buy hgh online and save your money
The site of overproduction of porphyrins in congenital erytropoietic porphyria is erythropoietic tissue. Bone marrow or stem cell transplantation replaces abnormally functioning cells with normal erythropoietic tissue. Some recent case reports suggest that these therapies can effect dramatic reversals of the clinical and biochemical abnormalities. At present, bone marrow or stem cell transplantation is the only curative treatment for patients with congenital erythropietic porphyrias. Although long-term results are lacking, this approach is the treatment of choice in severely disabled patients. Canadian pharmacy viagra and other medications.

Canadian pharmacy a lot of brand and generic medications.
Porphyria cutanea porphyria is the most common type of porphyria in the United States and Europe. Onset is usually during the fourth or fifth decade of life, and the disorder is manifested mainly as cutaneous symptoms and hepatopathy. Characteristic skin lesions are blistering and erosions on sun-exposed areas, mainly on the backs of the hands. Porphyria cutanea tarda is usually associated with chronic liver disease. Many patients consume excessive amounts of alcohol, and there is a high prevalence of hepatitis C infection among patients with porphyria cutanea tarda. In susceptible persons, hepatic siderosis is a common histopathologic finding, and accumulation of iron plays a pathogenetic role, probably by inhibiting uroporphyrinogen decarboxylase. In many countries, patients with porphyria cutanea tarda have an increased prevalence of genetic hemochromatosis, some 35 to 45% being heterozygous and 10 to 15% homozygous for major hemochromatosis mutations.
Female viagra
The main biochemical feature in porphyria cutanea tarda is massive overproduction of uroporphyrin. Urinary excretion of uroporphyrin in symptomatic patients is usually more than 2000 nmol per 24 hours (the normal value is less than 100 nmol). Other diagnostic characteristics are increased urinary 7-COOH porphyrin excretion, increased fecal isocoproporphyrin content, and a typical pattern in the plasma fluorescence spectrum.
Treatment
Predisposing factors such as alcohol, iron supplements, and estrogen preparations should be eliminated. In some cases this may result in clinical and biochemical remission.
Two specific and effective treatments for porphyria cutanea tarda are known, namely, iron removal by phlebotomy and low-dose chloroquine therapy. There is no general agreement on which is preferable; the use of chloroquine is more frequent in many European countries than in the United States, where chloroquine is recommended only if phlebotomy is contraindicated. In patients with significant iron overload, phlebotomy is the preferred therapy; in other cases, either treatment may be efficacious. Combination therapy with chloroquine and phlebotomy has also been reported to be useful.
In phlebotomy, 400 to 500 mL of blood is removed at weekly or biweekly intervals until the blood hemoglobin concentration falls to 100 to 110 grams per liter. Usually, 4 to 10 liters of blood must be removed before therapeutic effects are seen. Measurement of urinary excretion of uroporphyrin or total porphyrins is useful for monitoring the therapeutic effect, and phlebotomies can be discontinued when uroporphyrin excretion falls below 500 nmol per 24 hours. Clinical remission occurs usually within 6 months and biochemical remission within 12 months.
viagra super active at canadian health care mall.
In low-dose chloroquine therapy, chloroquine (Aralen) or hydroxychloroquine (Plaquenil) is administered orally 125 mg twice a week. The time needed for clinical and biochemical remission is usually the same as with phlebotomies.
After remission induced by phlebotomy or chloroquine, a relapse usually occurs within 1 to 2 years. Clinical relapse can be predicted by monitoring urinary excretion of porphyrins at intervals of 3 to 6 months. Treatment can be started if porphyrin levels are increasing (e.g., with uroporphyrin levels of 500 to 1000 nmol per 24 hours), which will prevent the occurrence of clinical manifestations. Canadian viagra online

Symptomatic Therapy
Canadian viagra online
Patients with acute attacks usually have symptoms that may necessitate medication or other therapies. Pain is typically severe, often requiring opiate analgesics for control; morphine, meperidine, or other opiates in normal doses may be used. For insomnia, chloral hydrate or benzodiazepines can be used. Chlorpromazine (Thorazine), up to 25 mg three or four times a day, can be given for major psychologic symptoms.
Seizures, which may occur during acute attacks, should not be treated with phenytoin or barbiturates because they are porphyric attack-precipitating drugs. Diazepam (Valium) and clonazepam (Klonopin) are probably safe and can be used in appropriate doses. Peripheral motor neuropathy tends to resolve slowly, with improvement to normal over weeks or months. Thus, it should be treated with effective physiotherapy and, if respiratory muscles are involved, with mechanical ventilation.
Prevention of Acute Attacks
After an acute attack the patient must be informed about precipitating factors to prevent future episodes. A list of unsafe drugs should be provided, and avoidance of alcohol consumption should be emphasized. Some authors recommend more strict regulation of dietary intake, e.g., a carbohydrate intake of 55 to 60% of total energy intake, but there is no evidence that this regimen improves the outcome. Our policy is to instruct the patient to avoid fasting or vigorous weight reduction but otherwise not to regulate food intake.
A few female patients with acute porphyria may have frequent symptoms associated with menstrual cycles. The symptoms usually develop during the premenstrual phase. Various hormonal manipulations have been tried for prevention of symptoms. Exogenous estrogens and progestins, e.g., oral contraceptive pills, have been reported to prevent attacks in some patients. These agents must be administered with caution, because female sex hormones are also regarded as precipitating drugs. In some patients, symptoms can be prevented by using gonadotropin-releasing hormone analogues. If there is a good response to one of these agents for several months, low doses of estradiol can be added to control the adverse effects of inadequate endogenous estrogens. Hormonal treatment for cyclical attacks is seldom needed for more than 1 to 3 years, which suggests that such attacks do not occur throughout the reproductive period of life. Human growth hormone online at family pharmacy shop. If hormonal manipulation does not control cyclical attacks, prophylactic heme administration can be used. The dose of heme in the prophylactic use is not established, but most treatment centers administer one infusion of 3 mg per kg weekly or, in milder cases, biweekly. An alternative approach is to administer heme only during the luteal phase of the cycle if the symptoms occur regularly premenstrually.
Management of acute attacks does not require identification of the exact type of acute porphyria, because the treatment and prevention are the same in all three types of acute porphyria. Prevention of attacks also includes evaluation of family members to find asymptomatic individuals with porphyria. In the asymptomatic phase, each of the acute porphyrias (acute intermittent porphyria, variegate porphyria, and hereditary coproporphyria) has characteristic biochemical findings. Thus, choosing appropriate laboratory tests for screening family members calls for precise identification of the type of porphyria. Biochemical tests identify most asymptomatic individuals with porphyria, but normal results do not exclude porphyria. The genes coding for the enzymes of heme biosynthesis are known, and various mutations have been described in patients with all three types of acute porphyria. Because of genetic heterogeneity, no universal DNA tests are available for acute porphyrias, but whenever the mutation is known a DNA analysis is the method of choice to diagnose or exclude porphyria among family members.
Also, asymptomatic family members should be informed about precipitating factors. Susceptibility to precipitating agents varies greatly, and many persons with latent porphyria tolerate them without harm. For that reason, in porphyric individuals who previously have been asymptomatic, strict avoiding of all drugs listed as unsafe is not necessary. Thus, for example, moderate alcohol intake is not necessarily prohibited, and contraceptive pills or postmenopausal hormone preparations can be allowed when appropriate. Cheap levitra

Treatment of the Acute Attack
Viagra super active
Treatment of acute porphyric attacks includes three different approaches: elimination of precipitating factors, specific therapy, and symptomatic treatment.
Elimination of Precipitating Factors
Acute porphyric attacks are often precipitated by factors such as certain drugs, excessive alcohol consumption, and fasting
Specific Therapy
Heme therapy and carbohydrate loading are specific therapies for acute porphyric attacks because these agents are able to reduce the overproduction of excess amounts of porphyrin precursors. Heme is much more effective in this regard than glucose.
Specific treatment is justified only when a patient has symptoms and signs compatible with an acute attack and increased excretion of porphobilinogen in the urine. The presence of symptoms without raised levels of porphobilinogen, or the finding of raised levels of porphobilinogen, 5-aminolevulinic acid, or porphyrins without symptoms, is not an indication for specific treatment. Cialis professional at cheap pharmacy.
Mild attacks are sometimes treated with glucose loading (by the oral or intravenous route, 400 to 500 grams daily) rather than heme. Severe attacks or symptoms that on the basis of clinical findings seem likely to progress should be treated with heme. When indicated, heme therapy should be started without delay because the effect of any treatment may be poor later in an attack after onset of neuropathy. Patients who have received heme may still require administration of some intravenous glucose and other nutrients for nutritional support.
The usual dose of heme is 3 mg per kg daily given intravenously for 4 consecutive days. The course may be shorter if the patient responds quickly or longer if the attack persists more than 4 days. There are two commercial heme preparations: hemin (Panhematin) and heme arginate (Normosang).
Heme arginate is the preferred preparation for intravenous use because it has been studied intensively and seems to have fewer side effects than hemin. Heme arginate has been registered in many European and other countries. In the United States, heme arginate has been under investigation but will be available soon. Hemin has been long available in the United States. Human growth hormone pharmacy

Porphyrias are a group of diseases that result from defective enzymes of heme biosynthesis. The seven different porphyrias correspond to an abnormality of a specific enzyme of the heme biosynthesis pathway. The genes coding for the enzymes are known in all porphyrias, and several mutations have been identified in porphyric patients. Canadian pharmacy
Two major types of clinical manifestations occur in porphyrias. Acute porphyric attack, which is characterized by abdominal pain and neurologic manifestations, is a feature in acute intermittent porphyria, variegate porphyria, and hereditary coproporphyria. In all three conditions the porphyrin precursors porphobilinogen and 5-aminolevulinic acid are accumulated during attacks. In other porphyrias cutaneous symptoms are the principal manifestations.
In symptomatic patients the specific porphyria can easily be diagnosed by specific laboratory tests. Most porphyrias are inherited in autosomal dominant fashion, but the penetrance of the disease varies greatly. In many porphyrias, the majority of patients remain asymptomatic throughout their lives. Cialis professional online without prescription. Biochemical tests are often inaccurate in the diagnosis of latent cases of porphyria. When the underlying mutation in an affected family is known, the DNA diagnosis is accurate, but the genetic heterogeneity of individual porphyrias restricts usefulness of this method.
ACUTE PORPHYRIAS
The acute porphyrias–acute intermittent porphyria, porphyria variegata, and hereditary coproporphyria– are characterized by episodic acute attacks. During an acute attack, symptoms include severe abdominal pain, vomiting, constipation, often pain in the extremities and in the back, and psychologic symptoms that range from anxiety to delirium. Urine may be dark or red in color because of increased amounts of porphobilin and porphyrins. Sometimes the disease progresses to peripheral motor neuropathy with the onset of seizures or cranial nerve palsies. Common clinical findings are hypertension and sinus tachycardia, and routine laboratory findings may include low serum sodium values. Canadian pharmacy news
All symptoms during acute attacks are nonspecific, and the diagnosis must be confirmed by appropriate laboratory tests. Laboratory diagnosis is easy, because during attacks all patients, irrespective of the type of porphyria, excrete great amounts of the porphyrin precursors porphobilinogen and 5-aminolevulinic acid. A rapid and relatively reliable qualitative test for porphobilinogen is available. A clearly positive qualitative test is a strong indicator of acute porphyria and allows beginning of therapy. However, the diagnosis must always be confirmed by quantitative tests for porphobilinogen and 5-aminolevulinic acid. During acute attacks the values are usually more than 10 times higher than reference values.